Regional redistribution of blood in unanesthetized rats after blood loss

Relative changes in local blood volume in 46 vascular regions of the body after moderate and severe blood loss are described. Moderate blood loss caused a redistribution of blood from the skin of the chest and hind limbs, most organs of the abdomen and pelvis, the muscular and bony tissues of the abdomen, pelvis, and limbs to the brain, heart, lungs, kidneys, stomach and to the muscles of the head and neck. After severe blood loss the changes were similar but the blood volume in the kidneys and stomach was reduced; a relative increase in the blood volume in the muscular and bony tissues of the thorax also was observed. The intensity of the redistributive response to severe blood loss was less than to a moderate blood loss.Central Research Laboratory, S. M. Kirov Leningrad Postgraduate Medical Institute. (Presented by Academician of the Academy of Medical Sciences of the USSR P. N. Veselkin.) Translated from Byulleten' Éksperimental'noi Biologii i Meditsiny, Vol. 82, No. 9, pp. 1045–1047, September, 1976.     

Small-cell carcinoma of the ovary in peritoneal fluid

Two cases of small-cell carcinoma of the ovary in the ascitic fluid and peritoneal/pelvic washings of a 30- and 28-yr-old woman, respectively, are presented and discussed. Smear preparations from the ascitic fluid showed loose clusters and single malignant cells with scant cytoplasm and nuclei with smooth to irregular nuclear membranes, granular chromatin, and small nucleoli. In the second case peritoneal/pelvic washing specimens contained clusters and single malignant cells with a moderate amount of cytoplasm and nuclei with smooth nuclear membranes, granular, clumped chromatin, and prominent nucleoli. Histology confirmed the diagnosis of small-cell carcinoma of the ovary. These are the first reported cases of this rare ovarian neoplasm present on fluid cytology. Its differentiation from other small-cell neoplasms on peritoneal fluid cytology from young women is discussed. Diagn Cytopathol 1994; 11:266–270. © 1994 Wiley-Liss, Inc.     

端粒酶转录酶及其调节相关蛋白与增殖细胞核抗原在卵巢上皮性肿瘤中的表达及临床意义

目的　探讨端粒酶转录酶 (hTERT)及端粒酶调节相关蛋白 (TRAP)与增殖细胞核抗原(PCNA)在卵巢上皮性肿瘤中的表达和临床意义。方法　收集 10 6例卵巢上皮性肿瘤 (恶性 5 4例 ,交界性 33例 ,良性 19例 )的临床资料 ,行hTERT、TRAP和PCNA 3种抗体的免疫组织化学标记链霉素卵白素生物素 (LSAB)法染色。对 87例恶性和交界性患者进行了随访 ,4 5例获结果 ,随访时间为 2～6 0个月。结果　hTERT蛋白的表达在良性 (4/ 19)和交界性 (90 9% ,30 / 33)以及良性和恶性(94 4 % ,5 1/ 5 4 )间的差异均有显著性 (P均 <0 0 0 1) ,TRAP蛋白的表达在良性 (4/ 15 )和恶性(77 8% ,2 8/ 36 )间的差异有显著性 (P <0 0 0 1) ;hTERT和TRAP蛋白的表达在卵巢癌Ⅰ、Ⅱ期和Ⅲ、Ⅳ期两组病例中的差异均无显著性 (P >0 0 5 ,P >0 3)。PCNA的表达在良性 (6 9± 5 9) %和交界性 (2 6 4± 17 8) %、良性和恶性 (5 1 8± 2 2 1) %以及交界性和恶性间的差异均有显著性 (P <0 0 1,P <0 0 0 1,P <0 0 5 )。 33例交界性患者全部存活 ,5 4例恶性患者中 35例 (6 4 8% )有转移 (包括 5例淋巴结转移 ) ,4例 (7 4 % )死亡。结论　hTERT和TRAP蛋白的表达与卵巢上皮性肿瘤的良恶性有关 ,但与其临床分期无关 ;hTERT和TRAP蛋白的表达相似     

A Randomized Study of Epithelial Ovarian Cancer: Is Chemotherapy Useful after Complete Remission?

Objective. The aim of this study is to verify whether consolidation chemotherapy with Cisplatin improves disease-free survival and/or overall survival in patients affected by epithelial ovarian cancer.Methods. A multicenter study examined 122 randomized patients in complete remission as judged by laparoscopy or laparotomy following first-line chemotherapy consisting of ACy (Adriamycin + Cyclophosphamide), PCy (Cisplatin + Cyclophosphamide), or Mitoxantrone + Carboplatin. Sixty-one of these patients were treated with 3 cycles of 5-Fluorouracil (FU) 500 mg/m2 for 5 days followed by Cisplatin at 100 mg/m2 on the 6th or 7th day every 28 days; the other 61 received no further treatment (nihil group).Results. Sixty patients in the Cisplatin arm were evaluable. There were 36 relapses in the FU+Cisplatin arm and 30 in the nihil arm. Peritoneal relapses were 25% for Cisplatin treatment vs. 16.4 % for nihil. There were 29 deaths in the Cisplatin arm vs. 27 for nihil. Median overall survival time (95 months with Cisplatin vs. 96 months in the nihil group) and median disease-free survival (66 months with Cisplatin vs. 73 in the nihil group) were similar in both arms (p=0.66 and p=0.41, respectively). There were no significant differences in tumor stage and grade between the two arms. Seven patients presented a second neoplasm during follow-up: six in the nihil arm, but only one patient in the Cisplatin arm. Death in these patients was due to the second neoplasm and not to progression of ovarian cancer.Conclusion. Three courses of additional platinum+FU treatment after five cycles of first-line chemotherapy without FU produced no increase in overall survival or disease-free survival.     

Simultaneous evaluation of basal FSH and oestradiol response to GnRH analogue (F-G-test) allows effective drug regimen selection for IVF

To determine whether preliminary assessment of ovarian reserve by simultaneous evaluation of basal follicle-stimulating hormone (FSH) and oestradiol response to gonadotrophin releasing hormone (GnRH) analogue (F-G-test) can be used to tailor individually the drug regimen for ovarian stimulation, the in-vitro fertilization (IVF) results of 238 patients were retrospectively analysed. Sixty-two women with abnormal response to the test (DeltaE2 <180 pmol/l and/or FSH >9.5 mIU/ml) had commenced buserelin nasal spray in the mid-luteal phase and discontinued it on cycle day 1. Ovarian stimulation was started on cycle day 3 with 375 IU/day of gonadotrophin. Fifty-three patients completed the treatment cycle (group A). A total of 176 women with normal response to the test (DeltaE2 >180 pmol/l and FSH <9.5 mIU/ml) had continued the GnRH analogue throughout the stimulation cycle and a starting dose of 225 IU/day of gonadotrophin was used from cycle day 3. A total of 158 patients completed the treatment cycle (group B). Group A had significantly higher age (34.9 +/- 4.2 versus 33.2 +/- 4.2) (P < 0.05) and basal FSH (9.2 +/- 3.8 versus 7.0 +/- 2.2) (P < 0.05) and required a higher total dose of gonadotrophin. The numbers of oocytes retrieved and embryos transferred were significantly lower. However, fertilization, clinical pregnancies, and implantation rates were similar in both groups. It was concluded that simultaneous evaluation of basal FSH and oestradiol response to GnRH analogue can be useful in identifying subcategories of women with reduced ovarian reserve who may benefit from reduced GnRH analogue administration and a higher starting dose of gonadotrophin.     

卵巢女性化性索间质性肿瘤39例临床病理分析

重新复查我院1960～1980年收治原诊为卵巢女性化性索间质性肿瘤39例的病理切片,可疑者再切片作特殊染色,复查后纠正了11例误诊病例,对确诊的28例的临床表现、病理特征、随访结果及预后等进行了分析。讨论了误诊病例的病理后,建议此类肿瘤中的粒层细胞瘤命名为“恶性粒层细胞瘤”,其恶性度与细胞分级密切相关,预后与卵巢外扩散及治疗是否彻底相关。     

CT在卵巢肿瘤中的应用价值

目的 :评价卵巢肿瘤的CT诊断价值。方法 :搜集经手术和病理证实的 2 0例卵巢肿瘤 ,对其CT表现作回顾性分析。结果 :2 0例卵巢肿瘤中 ,单纯性卵巢囊肿 2例 ,卵巢成熟性畸胎瘤 4例 ,卵巢甲状腺肿 1例 ,卵巢囊腺瘤 3例 ,卵巢无性细胞瘤1例 ,卵巢颗粒细胞瘤 1例 ,卵巢癌 8例。结论 :CT对卵巢肿瘤的定位及定性诊断有重要的价值 ,但对卵巢良、恶性肿瘤的鉴别须结合病史和年龄。     

人卵巢癌SCID小鼠移植瘤模型、细胞系建立及其生物学特性研究

目的建立人卵巢癌SCID小鼠移植瘤模型和相应体外细胞系.方法将病理证实的人卵巢浆液性乳头状腺癌手术切除标本移植于SCID小鼠皮下,成瘤后行鼠间传代,取移植瘤细胞体外分离培养、传代和建系,并应用细胞、分子生物学手段对移植瘤和建系细胞进行一系列生物学特性检测.结果历时14个月传至5代,皮下移植瘤存活率为90%,持续6个月,体外建系(OVA-319)细胞生长稳定.镜下观察组织形态学和超微结构符合原肿瘤组织基本特征;染色体分布在12～46条之间,多为异倍体,显示人类肿瘤异常染色体;流式细胞术和RT-PCR技术分析原代、体内移植瘤和OVA-319细胞结果一致,表现为瘤细胞生长活跃、细胞周期分布相仿,MAGE-2基因在mRNA水平异常表达.结论人卵巢癌SCID小鼠移植瘤模型和OVA-319细胞系为人类肿瘤的研究提供了良好的实验材料.     

诊断卵巢恶性肿瘤最佳标志群的研究

目的研究22种肿瘤标志(TM)对诊断卵巢恶性肿瘤(OMN)的价值,选择最佳诊断标志群.方法用高压液相色谱法、自动生化仪检测法、酶联免疫法检测.结果单项TM的敏感性≥60%者分别为腐胺(100%)、精脒(84%)、CA125(80%)、唾液酸(SA)(70.4%)、铁蛋白(61.2%)、肿瘤特异生长因子(TS-GF)(60.9%)和CA153(60%).有效率≥80%者分别是TSGF(88.6%)、精胺(86.6%)、精脒(83.8%)、CA153(81.2%)、SA(81.1%)、腐胺(81.0%)和CA125(80%).最佳标志群为CA125、TSGF和SA.结论CA125是诊断OMN最敏感的TM,其次是SA、铁蛋白和TSGF.TM联合测定能提高诊断的有效性,其中以CA125、TSGF和SA联合测定效果较好.     

肾透明细胞癌和卵巢癌与HLAI类抗原关联性研究

目的 分析HLAI类抗原与肾透明细胞癌和卵巢癌的关联性。为确定与这些肿瘤的易感性和抵抗性有关的基因。并为寻找肿瘤特异性的抗原肽,开展肿瘤免疫诊断和治疗奠定基础。方法 实验采用微量淋巴细胞毒试验。分析82例肾透明细胞癌和21例卵巢癌患者外周血HLA-A抗原和-B抗原的抗原频率。结果 与肾透明细胞癌和卵巢癌关联的HLAI类完全不同,其中与肾透明细胞癌关联的位点大大多于卵巢癌的位点,有A9、A11、A28、BG15、B22、B27和B40;而与卵巢癌关联的HLAI类抗原位点只有A10、A36和B12,且卵巢癌关联A10抗原保持显著关联。结论 HLAI类抗原关联性研究显示,HLA-A10可能为卵巢癌提供抵抗性。